Suchergebnisse - "Lu-177 PSMA"

Evaluation of Tumor Burden Response to Single-cycle of Lu-177 PSMA Treatment with Whole Body Scintigraphic Planar Images in Prostate Cancer Patients

Autoren: Emine ACAR Ayşegül AKSU Ender Berat ELLİDOKUZ et al.

Quelle: Volume: 7, Issue: 1 471-478
Journal of Basic and Clinical Health Sciences

Schlagwörter: prostate cancer, Lu-177 PSMA, radioligand therapy, scintigraphy, 03 medical and health sciences, 0302 clinical medicine, Health Care Administration, Sağlık Kurumları Yönetimi, 3. Good health

Dateibeschreibung: application/pdf

Zugangs-URL: https://avesis.deu.edu.tr/publication/details/c0dcf9f1-9faa-40fe-bc8c-f1bf68c6ceb8/oai
https://dergipark.org.tr/tr/pub/jbachs/issue/75677/1189713

Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points

Autoren: Gefei Chen Zhonglin Lu Han Jiang et al.

Quelle: Front Med (Lausanne)
Frontiers in Medicine, Vol 10 (2023)
Chen, Gefei; Lu, Zhonglin; Jiang, Han; Afshar-Oromieh, Ali; Rominger, Axel; Shi, Kuangyu; Mok, Greta S P (2023). Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points. Frontiers in medicine, 10(1246881), p. 1246881. Frontiers 10.3389/fmed.2023.1246881 <http://dx.doi.org/10.3389/fmed.2023.1246881>

Schlagwörter: Medicine (General), R5-920, dosimetry, SPECT, curve fitting, Lu-177 PSMA, Medicine, 610 Medicine & health, single time point

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38020081
https://doaj.org/article/85544314231e4647b74751acca53eb92
https://boris.unibe.ch/189659/

Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen

Autoren: Kai Huang Imke Schatka Julian M. M. Rogasch et al.

Quelle: Ann Nucl Med

Schlagwörter: Male, Glutamate Carboxypeptidase II, Lu-177 PSMA, Lutetium, Ligands, Predictive score, 03 medical and health sciences, 0302 clinical medicine, Glutamate Carboxypeptidase II/metabolism [MeSH], Prostatic Neoplasms, Castration-Resistant/pathology [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Humans [MeSH], Neoplasm Metastasis [MeSH], Radioligand therapy, Treatment Outcome [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Antigens, Surface/metabolism [MeSH], Lutetium/therapeutic use [MeSH], Original Article, Male [MeSH], Radioisotopes/therapeutic use [MeSH], Metastatic castration-resistant prostate cancer, Prostatic Neoplasms, Castration-Resistant/radiotherapy [MeSH], Humans, Neoplasm Metastasis, Aged, Retrospective Studies, Aged, 80 and over, Radioisotopes, Middle Aged, Prostate-Specific Antigen, 3. Good health, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Antigens, Surface, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s12149-020-01567-3.pdf
https://pubmed.ncbi.nlm.nih.gov/33351172
https://www.ncbi.nlm.nih.gov/pubmed/33351172
https://link.springer.com/content/pdf/10.1007/s12149-020-01567-3.pdf
https://pubmed.ncbi.nlm.nih.gov/33351172/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902572
https://link.springer.com/article/10.1007/s12149-020-01567-3
https://europepmc.org/article/PMC/PMC7902572
https://repository.publisso.de/resource/frl:6471492
https://refubium.fu-berlin.de/handle/fub188/35470
https://doi.org/10.17169/refubium-35185
https://doi.org/10.1007/s12149-020-01567-3

Lu-177 Labeled Somatostatin Receptors and PSMA Dosimetry

Autoren: Toklu, Turkay Kozanlilar, Burcu Yeyın, Nami et al.

Weitere Verfasser: Toklu, Turkay Kozanlilar, Burcu Yeyın, Nami et al.

Schlagwörter: Radiotherapy, Radiopharmaceutical Agent, Lu-177 Psma-targeted Ligands, Lu-177 Somatostatin Receptor Ligands, Lu-177 Dosimetry, Lutetium 177, Clinical Practice Guideline, Review, Lacrimal Gland, Salivary Gland, Prostate Adenocarcinoma, Neuroendocrine Tumors, Prostate Specific Membrane Antigen, Somatostatin Receptor, Bone Marrow, Dosimetry, Nuclear Medicine, Somatostatin, Neuroendocrine Tumor, Human

Zugangs-URL: https://hdl.handle.net/20.500.12831/25859

Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177 Lu-labeled prostate-specific membrane antigen

Autoren: Huang, Kai Schatka, Imke Rogasch, Julian M. M. et al.

Schlagwörter: Predictive score, Radioligand therapy, Metastatic castration-resistant prostate cancer, Lu-177 PSMA, ddc:610

Dateibeschreibung: application/pdf

Verfügbarkeit: https://refubium.fu-berlin.de/handle/fub188/35470
https://doi.org/10.17169/refubium-35185
https://doi.org/10.1007/s12149-020-01567-3

Clinical outcome of Lu-177 PSMA in metastatic castration-resistant prostate cancer: An initial experience from a tertiary care cancer hospital

Autoren: Anurag Sharma Ganesan Karthikeyan Manoj Gupta et al.

Quelle: Annals of Cancer Research and Therapy. 2020, 28(2):156

Theranostics in the Indian Subcontinent: Opportunities, Challenges, and the Path Forward.

Autoren: Sharma P; Department of Nuclear Medicine, Apollo Multispeciality Hospital, 58, Canal Circular Road, Kolkata, 700054 India.

Quelle: Nuclear medicine and molecular imaging [Nucl Med Mol Imaging] 2025 Oct; Vol. 59 (5), pp. 360-370. Date of Electronic Publication: 2025 Jun 14.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Springer Country of Publication: Germany NLM ID: 101530478 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1869-3474 (Print) Linking ISSN: 18693474 NLM ISO Abbreviation: Nucl Med Mol Imaging Subsets: PubMed not MEDLINE

Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals.

Autoren: Yechiel Y Chicheportiche A Keidar Z et al.

Quelle: PET clinics [PET Clin] 2024 Jul; Vol. 19 (3), pp. 389-399. Date of Electronic Publication: 2024 Apr 27.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Elsevier Saunders Country of Publication: United States NLM ID: 101260152 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-9809 (Electronic) Linking ISSN: 15568598 NLM ISO Abbreviation: PET Clin Subsets: MEDLINE

MeSH-Schlagworte: Prostatic Neoplasms*/diagnostic imaging , Prostatic Neoplasms*/radiotherapy , Prostatic Neoplasms*/pathology , Radiopharmaceuticals*/therapeutic use, Humans ; Male ; Positron Emission Tomography Computed Tomography/methods ; Beta Particles/therapeutic use

A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?

Autoren: Gupta M Karthikeyan G Choudhury PS et al.

Quelle: Cancer investigation [Cancer Invest] 2020 Sep; Vol. 38 (8-9), pp. 486-492. Date of Electronic Publication: 2020 Sep 14.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: England NLM ID: 8307154 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-4192 (Electronic) Linking ISSN: 07357907 NLM ISO Abbreviation: Cancer Invest Subsets: MEDLINE

MeSH-Schlagworte: Dipeptides/*therapeutic use , Heterocyclic Compounds, 1-Ring/*therapeutic use , Lutetium/*therapeutic use , Prostatic Neoplasms, Castration-Resistant/*radiotherapy , Radioisotopes/*therapeutic use , Radiopharmaceuticals/*therapeutic use, Clinical Trials, Phase II as Topic ; Humans ; Male ; Prostate-Specific Antigen ; Randomized Controlled Trials as Topic ; Translational Research, Biomedical